{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:28:55Z","timestamp":1794475735369,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-022-02344-z","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T22:02:22Z","timestamp":1652220142000},"page":"3449-3457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The impact of laboratory findings and optical coherence tomography biomarkers on response to intravitreal anti-VEGF treatment in patients with retinal vein occlusion"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-1024","authenticated-orcid":false,"given":"Irini","family":"Chatziralli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kazantzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Kroupis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genovefa","family":"Machairoudia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Theodossiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Theodossiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros N.","family":"Sergentanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"2344_CR1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I (2019) Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health 9:010427","journal-title":"J Glob Health"},{"key":"2344_CR2","first-page":"133","volume":"98","author":"R Klein","year":"2000","unstructured":"Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the beaver dam eye study. Trans Am Ophthalmol Soc 98:133\u2013141","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2344_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY; International Eye Disease Consortium","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY; International Eye Disease Consortium (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117:313\u2013319","journal-title":"Ophthalmology"},{"key":"2344_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000455278","volume":"58","author":"JB Jonas","year":"2017","unstructured":"Jonas JB, Mon\u00e9s J, Glacet-Bernard A, Coscas G (2017) Retinal vein occlusions. Dev Ophthalmol 58:139\u2013167","journal-title":"Dev Ophthalmol"},{"key":"2344_CR5","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","volume":"117","author":"RL McIntosh","year":"2010","unstructured":"McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, Kowalski JW, Nguyen HP, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117:1113\u20131123","journal-title":"Ophthalmology"},{"key":"2344_CR6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1517\/14712598.2015.1086744","volume":"15","author":"I Chatziralli","year":"2015","unstructured":"Chatziralli I, Nicholson L, Sivaprasad S, Hykin P (2015) Intravitreal steroid and anti-vascular endothelial growth agents for the management of retinal vein occlusion: evidence from randomized trials. Expert Opin Biol Ther 15:1685\u20131697","journal-title":"Expert Opin Biol Ther"},{"key":"2344_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, Wolf S, Loewenstein A (2019) Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA). Ophthalmologica 242:123\u2013162","journal-title":"Ophthalmologica"},{"key":"2344_CR8","first-page":"236","volume":"8","author":"K Spooner","year":"2019","unstructured":"Spooner K, Hong T, Fraser-Bell S, Chang A (2019) Current outcomes of Anti-VEGF therapy in the treatment of macular Edema secondary to central retinal vein occlusions: a systematic review and meta-analysis. Asia Pac J Ophthalmol 8:236\u2013246","journal-title":"Asia Pac J Ophthalmol"},{"key":"2344_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000497492","volume":"242","author":"K Spooner","year":"2019","unstructured":"Spooner K, Hong T, Fraser-Bell S, Chang AA (2019) Current Outcomes of Anti-VEGF therapy in the treatment of macular oedema secondary to branch retinal vein occlusions: a meta-analysis. Ophthalmologica 242:163\u2013177","journal-title":"Ophthalmologica"},{"key":"2344_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01702-y","author":"A Lotery","year":"2021","unstructured":"Lotery A, Clemens A, Tuli R, Xu X, Shimura M, Nardi M, Ziemssen F, Dunger-Baldauf C, Tadayoni R, LUMINOUS\u2122 study group, (2021) Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global. LUMINOUS study Eye (in press). https:\/\/doi.org\/10.1038\/s41433-021-01702-y","journal-title":"LUMINOUS study Eye (in press)"},{"key":"2344_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234739","volume":"15","author":"I Pearce","year":"2020","unstructured":"Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, Creuzot-Garcher C, Spital G, Sakamoto T, Dunger-Baldauf C, McAllister IL, all the LUMINOUS\u2122 study investigators, (2020) Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global. LUMINOUS study PLoS One 15:e0234739","journal-title":"LUMINOUS study PLoS One"},{"key":"2344_CR12","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041\u20132049","journal-title":"Ophthalmology"},{"key":"2344_CR13","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594\u20131602","journal-title":"Ophthalmology"},{"key":"2344_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","volume":"123","author":"WL Clark","year":"2016","unstructured":"Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y, Campochiaro PA (2016) Intravitreal Aflibercept for Macular Edema following branch retinal Vein Occlusion: 52-Week results of the VIBRANT study. Ophthalmology 123:330\u2013336","journal-title":"Ophthalmology"},{"key":"2344_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamaophthalmol.2018.6111","volume":"137","author":"Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group","year":"2019","unstructured":"Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group (2019) Month 12 outcomes after treatment change at month 6 among poor responders to aflibercept or bevacizumab in eyes with macular Edema secondary to central or hemiretinal vein occlusion: a secondary analysis of the SCORE2 study. JAMA Ophthalmol 137:281\u2013287","journal-title":"JAMA Ophthalmol"},{"key":"2344_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00417-017-3613-1","volume":"255","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Theodossiadis G, Moschos MM, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefes Arch Clin Exp Ophthalmol 255:1093\u20131100","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2344_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.sjopt.2017.09.009","volume":"31","author":"A Ozkaya","year":"2017","unstructured":"Ozkaya A, Tulu B, Garip R (2017) Aflibercept in macular edema secondary to retinal vein occlusion: a real life study. Saudi J Ophthalmol 31:211\u2013215","journal-title":"Saudi J Ophthalmol"},{"key":"2344_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40942-016-0054-7","volume":"3","author":"P Phadikar","year":"2017","unstructured":"Phadikar P, Saxena S, Ruia S, Lai TY, Meyer CH, Eliott D (2017) The potential of spectral domain optical coherence tomography imaging based retinal biomarkers. Int J Retina Vitreous 3:1","journal-title":"Int J Retina Vitreous"},{"key":"2344_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/17434440.2020.1755256","volume":"17","author":"J Vira","year":"2020","unstructured":"Vira J, Marchese A, Singh RB, Agarwal A (2020) Swept-source optical coherence tomography imaging of the retinochoroid and beyond. Expert Rev Med Devices 17:413\u2013426","journal-title":"Expert Rev Med Devices"},{"key":"2344_CR20","doi-asserted-by":"crossref","first-page":"251584141984024","DOI":"10.1177\/2515841419840249","volume":"11","author":"AC Onishi","year":"2019","unstructured":"Onishi AC, Fawzi AA (2019) An overview of optical coherence tomography angiography and the posterior pole. Ther Adv Ophthalmol 11:2515841419840249","journal-title":"Ther Adv Ophthalmol"},{"key":"2344_CR21","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1097\/IAE.0000000000001070","volume":"36","author":"IP Chatziralli","year":"2016","unstructured":"Chatziralli IP, Sergentanis TN, Sivaprasad S (2016) Hyperreflective foci as an independent visual outcome predictor in macular edema dye to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina 36:2319\u20132328","journal-title":"Retina"},{"key":"2344_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/IAE.0000000000001579","volume":"38","author":"I Chatziralli","year":"2018","unstructured":"Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P (2018) Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina 38:559\u2013568","journal-title":"Retina"},{"key":"2344_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/tvst.10.3.31","volume":"10","author":"T Etheridge","year":"2021","unstructured":"Etheridge T, Dobson ETA, Wiedenmann M, Oden N, VanVeldhuisen P, Scott IU, Ip MS, Eliceiri KW, Blodi BA, Domalpally A (2021) Ellipsoid zone defects in retinal vein occlusion correlates with visual acuity prognosis: SCORE2 report 14. Transl Vis Sci Technol 10:31","journal-title":"Transl Vis Sci Technol"},{"key":"2344_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13167-021-00233-6","volume":"12","author":"DY Khokhlova","year":"2021","unstructured":"Khokhlova DY, Drozdova EA, Kurysheva NI, Loskutov IA (2021) Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach. EPMA J 12:57\u201366","journal-title":"EPMA J"},{"key":"2344_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.02.008","author":"P Sen","year":"2021","unstructured":"Sen P, Gurudas S, Ramu J, Patrao N, Chandra S, Rasheed R, Nicholson L, Peto T, Sivaprasad S, Hykin P (2021) Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular Edema secondary to central retinal vein occlusion. Ophthalmol Retina (in press). https:\/\/doi.org\/10.1016\/j.oret.2021.02.008","journal-title":"Ophthalmol Retina (in press)"},{"key":"2344_CR26","first-page":"321","volume":"7","author":"VG Madanagopalan","year":"2018","unstructured":"Madanagopalan VG, Kumari B (2018) Predictive value of baseline biochemical parameters for clinical response of macular Edema to bevacizumab in eyes with central retinal vein occlusion: a retrospective analysis. Asia Pac J Ophthalmol 7:321\u2013330","journal-title":"Asia Pac J Ophthalmol"},{"key":"2344_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000509171","volume":"64","author":"J Rao","year":"2021","unstructured":"Rao J, Wu N, Qu X, Hu Y, Wu Y, Cheng Y, Yan L, Huang H, Li S, Shi L, Wu X (2021) The role of serum inflammation-based factors in anti-vascular endothelial growth factor treatment for macular Edema secondary to retinal vein occlusion and its subtypes. Ophthalmic Res 64:237\u2013245","journal-title":"Ophthalmic Res"},{"key":"2344_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1089\/jop.2020.0130","volume":"37","author":"E Vural","year":"2021","unstructured":"Vural E, Hazar L (2021) Assessment of inflammation biomarkers in diabetic macular Edema treated with intravitreal dexamethasone implant. J Ocul Pharmacol Ther 37:430\u2013437","journal-title":"J Ocul Pharmacol Ther"},{"key":"2344_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/jop.2019.0011","volume":"35","author":"R Matsushima","year":"2019","unstructured":"Matsushima R, Noma H, Yasuda K, Goto H, Shimura M (2019) Role of cytokines in Ranibizumab therapy for macular Edema in patients with central retinal Vein occlusion. J Ocul Pharmacol Ther 35:407\u2013412","journal-title":"J Ocul Pharmacol Ther"},{"key":"2344_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.4161\/cbt.9.9.11691","volume":"9","author":"G Vitale","year":"2010","unstructured":"Vitale G, Dicitore A, Gentilini D, Cavagnini F (2010) Immunomodulatory effects of VEGF: clinical implications of VEGF-targeted therapy in human cancer. Cancer Biol Ther 9:694\u2013698","journal-title":"Cancer Biol Ther"},{"key":"2344_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000440848","volume":"55","author":"C Farinha","year":"2015","unstructured":"Farinha C, Marques JP, Almeida E, Baltar A, Santos AR, Melo P, Costa M, Figueira J, Cachulo ML, Pires I, Silva R (2015) Treatment of Retinal Vein Occlusion with Ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 55:10\u201318","journal-title":"Ophthalmic Res"},{"key":"2344_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ajo.2013.05.039","volume":"156","author":"R Sophie","year":"2013","unstructured":"Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, Do DV, Solomon S, Sodhi A, Gehlbach P, Duh E, Baranano D, Campochiaro PA (2013) Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. Am J Ophthalmol 156:693\u2013705","journal-title":"Am J Ophthalmol"},{"key":"2344_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000462976","volume":"58","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG, Theodossiadis P (2017) Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res 58:203\u2013208","journal-title":"Ophthalmic Res"},{"key":"2344_CR34","doi-asserted-by":"publisher","first-page":"6645452","DOI":"10.1155\/2021\/6645452","volume":"2021","author":"S Song","year":"2021","unstructured":"Song S, Yu X, Zhang P, Dai H (2021) Changes in macular microvascular structure in macular Edema secondary to branch retinal vein occlusion treated with antivascular endothelial growth factor for one year. J Ophthalmol 2021:6645452","journal-title":"J Ophthalmol"},{"key":"2344_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.ophtha.2019.07.018","volume":"126","author":"R Sophie","year":"2019","unstructured":"Sophie R, Wang PW, Channa R, Quezada-Ruiz C, Clark A, Campochiaro PA (2019) Different factors associated with 2-year outcomes in patients with branch versus central retinal vein occlusion treated with ranibizumab. Ophthalmology 126:1695\u20131702","journal-title":"Ophthalmology"},{"key":"2344_CR36","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1001\/jamaophthalmol.2019.3305","volume":"137","author":"Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S; LEAVO Study Group","year":"2019","unstructured":"Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S; LEAVO Study Group (2019) Clinical effectiveness of intravitreal therapy with Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: a randomized clinical trial. JAMA Ophthalmol 137:1256\u20131264","journal-title":"JAMA Ophthalmol"},{"key":"2344_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/IAE.0000000000001566","volume":"38","author":"M Okamoto","year":"2018","unstructured":"Okamoto M, Yamashita M, Sakamoto T, Ogata N (2018) Choroidal blood flow and thickness as predictors for response to anti-vascular endothelial growth factor therapy in macular edema secondary to branch retinal vein occlusion. Retina 38:550\u2013558","journal-title":"Retina"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02344-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02344-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T18:07:49Z","timestamp":1666462069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02344-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["2344"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02344-z","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"assertion":[{"value":"28 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, or other equity interest), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants gave written informed consent for participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants gave written informed consent for their data to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board of Attikon Hospital, Athens, Greece.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}